A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

StatusRecruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 156 → 159 locations
  2. Study sites: 155 to 156
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 2 of 36 entries
  3. Trial sites expanded: 151 → 155 locationsv26
  4. Study sites: 150 to 151v25
  5. Study sites: 149 to 150v24
  6. Trial sites expanded: 144 → 149 locationsv23
  7. Trial sites expanded: 140 → 144 locationsv22
  8. Trial sites expanded: 136 → 140 locationsv21
  9. Site details revised at 1 of 136 sitesv20
  10. Study sites: 134 to 136v19
  11. Study sites: 133 to 134v18
  12. Trial sites expanded: 129 → 133 locationsv17
  13. Study sites: 127 to 129v16
  14. Study sites: 126 to 127v15
  15. Study sites: 125 to 126v14
  16. Trial sites expanded: 122 → 125 locationsv13
  17. Study sites: 120 to 122v12
  18. Trial sites expanded: 117 → 120 locationsv11
  19. Study sites: 116 to 117v10
  20. Trial sites expanded: 94 → 116 locationsv9
  21. Study sites: 90 to 94v8
  22. Study sites: 79 to 90v7
  23. Study sites: 60 to 79v6
  24. Study sites: 31 to 60
    • Eligibility criteria expanded, about 3 words
    v5
  25. Primary completion date: Aug 29, 2028 to Jan 7, 2030
    • Study sites: 26 to 31
    • Secondary endpoints: details revised at 36 of 36 entries
    v4
  26. Study sites: 4 to 26
    • Start date changed from estimate of Nov 1, 2025 to Nov 28, 2025
    v3
  27. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    v2
  28. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
Prostate Cancer
2,555 trials monitored
See 170 trials at risk
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Trial Details
NCT Number NCT07213674
Lead Sponsor Amgen
Conditions
(from sponsor)		 Metastatic Castration-resistant Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov